Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
13 hedge funds and large institutions have $8.18M invested in Soleno Therapeutics in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
8% more funds holding
Funds holding: 12 → 13 (+1)
0.01% less ownership
Funds ownership: 0.46% → 0.46% (-0.01%)
30% less capital invested
Capital invested by funds: $11.7M → $8.18M (-$3.55M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$8.76K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$4.22K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.69K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$788 |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$371 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bollard Group
Boston,
Massachusetts
|
-$107K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$17K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.03K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VC
1
Vivo Capital
Palo Alto,
California
| $7.36M | – | – | – |
|
|
2
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $288K | +$371 | +8 | +0.1% |
|
|
PAI
3
Palo Alto Investors
Palo Alto,
California
| $212K | – | – | – |
|
|
SM
4
Sabby Management
Miami Beach,
Florida
| $127K | +$8.76K | +189 | +6% |
|
|
BG
5
Bollard Group
Boston,
Massachusetts
| $96K | -$107K | -2,308 | -47% |
|
6
BlackRock
New York
| $39K | +$324 | +7 | +0.7% |
|
|
7
Vanguard Group
Malvern,
Pennsylvania
| $30K | -$6.03K | -130 | -14% |
|
8
Goldman Sachs
New York
| $15K | – | – | – |
|
9
Northern Trust
Chicago,
Illinois
| $7K | – | – | – |
|
|
10
Bank of America
Charlotte,
North Carolina
| $3K | +$4.22K | +91 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| $2K | +$2.69K | +58 | New |
|
12
Morgan Stanley
New York
| $1K | – | – | – |
|
|
13
Creative Planning
Overland Park,
Kansas
| $1K | +$788 | +17 | New |
|
|
14
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$20K | -396 | Closed |
|
|
15
Citadel Advisors
Miami,
Florida
| – | -$17K | -327 | Closed |
|
SLNO Hedge Fund Activity: Q2 2017 in Review
13 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2017, worth a combined $8.18M — down 30% from $11.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SLNO positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, adding an estimated $8.76K. The largest seller was Bollard Group, cutting an estimated $107K.
- 13 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2017, up from 12 in Q1 2017.
- Funds reported $8.18M of Soleno Therapeutics stock for Q2 2017, down 30% quarter-over-quarter.
- 3 funds opened new Soleno Therapeutics positions in Q2 2017 and 2 closed out, a net change of +1 holder.
- The largest Soleno Therapeutics buyer in Q2 2017 was Sabby Management, an estimated $8.76K added.
- The largest Soleno Therapeutics seller in Q2 2017 was Bollard Group, an estimated $107K sold.
Based on aggregated 13F filings for Q2 2017.